Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT
3D MEDICINES AND CATUG BIOTECHNOLOGY JOIN FORCES TO ADVANCE TLNP-DELIVERED IN VIVO CAR-T/NK THERAPY DEVELOPMENT

The Company is pleased to announce that on 20th August 2025, 3D Medicines Inc. (the "**Company**" or "**3D Medicines**") entered into a framework agreement on strategic cooperation (the "**Framework Agreement**") with CATUG Biotechnology.

Pursuant to the Framework Agreement, the parties will leverage 3D Medicines' proprietary self-developed advanced mRNA R&D platform and LNP delivery system (3D-LNP), combined with CATUG Biotechnology's expertise and advantages in large-scale mRNA production, to strengthen collaboration in areas including targeted LNP delivery (tLNP), cancer vaccines, and in vivo CAR-T/NK. The specific implementation of these obligations is subject to further formal agreements. This collaboration marks 3D Medicines is accelerating expansion in mRNA research, providing solid production capacity support for subsequent clinical development and future commercialization of its innovative therapeutic products based on mRNA-LNP technology.

3D Medicines has established mRNA technology and LNP delivery platforms with independent intellectual property rights globally. The mRNA technology platform is a multi-module cancer vaccine analysis platform (3D-PreciseAg) built using advanced AI technology. It supports massive antigen multi-omics analysis and optimal new antigen selection. Meanwhile, 3D Medicines owns an AI-enhanced LNP delivery technology platform with independent intellectual property rights. Using AI algorithms, it can screen thousands of compounds and resulting in a diverse portfolio of LNP products capable of covering various delivery scenarios. This enhances the delivery efficiency and targeting precision of mRNA cancer vaccines, in vivo CAR-T/NK immune cell therapies, and other drugs, while significantly reducing toxicity.

The Board believes the cooperation under this Framework Agreement aligns with the overall interests of the Company and its shareholders.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong
August 20, 2025

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.